Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

Related Articles

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

5 months ago

Is Microsoft's $50 Billion Global South AI Bet a Game Changer

6 months ago

Is Highmark's Digital Therapeutics Coverage a Game Changer for Investors

3 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

3 months ago

Category

You may also like

Stock News•1 months ago

NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy

NextCure and Avere Therapeutics will merge to advance AVR-001, an oral IL-23 therapy. Phase 1b psoriasis data supports its potential as a once-weekly treatment.

NXTC

Share

Stock News•1 months ago

Why Q32 Bio Stock Skyrocketed Today

Q32 Bio shares surged after the company announced progress on a potential treatment for a common autoimmune disease.

QTTB

Share

Stock News•1 months ago

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Cue Biopharma appointed Dominic Borie, M.D., Ph.D., as CMO and Head of R&D, as the company advances clinical programs in allergic and autoimmune diseases.

CUE

Share

Stock News•1 months ago

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics is positioned to pioneer autoimmune CAR T with miv-cel, targeting FDA approval by late 2026 after regulatory alignment for a rolling BLA submission in SPS. The company holds $236M...

CAR

Share